Takeda Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

Takeda Pharmaceutical CEO'su Christophe P. Weber, Jun2014 tarihinde atandı, in görev süresi 11.92 yıldır. in toplam yıllık tazminatı ¥ 2.16B olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.6% maaş ve 84.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.055% ine doğrudan sahiptir ve bu hisseler $ 28.16M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5 yıl ve 9.9 yıldır.

Anahtar bilgiler

Christophe P. Weber

İcra Kurulu Başkanı

JP¥2.2b

Toplam tazminat

CEO maaş yüzdesi	15.59%
CEO görev süresi	11.9yrs
CEO sahipliği	0.05%
Yönetim ortalama görev süresi	5yrs
Yönetim Kurulu ortalama görev süresi	9.9yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Christophe P. Weber'un ücretlendirmesi Takeda Pharmaceutical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Mar 31 2026	n/a	n/a	JP¥192b
Dec 31 2025	n/a	n/a	JP¥113b
Sep 30 2025	n/a	n/a	JP¥33b
Jun 30 2025	n/a	n/a	JP¥137b
Mar 31 2025	JP¥2b	JP¥337m	JP¥108b
Dec 31 2024	n/a	n/a	JP¥208b
Sep 30 2024	n/a	n/a	JP¥290b
Jun 30 2024	n/a	n/a	JP¥150b
Mar 31 2024	JP¥2b	JP¥317m	JP¥144b
Dec 31 2023	n/a	n/a	JP¥178b
Sep 30 2023	n/a	n/a	JP¥192b
Jun 30 2023	n/a	n/a	JP¥301b
Mar 31 2023	JP¥2b	JP¥295m	JP¥317b
Dec 31 2022	n/a	n/a	JP¥275b
Sep 30 2022	n/a	n/a	JP¥213b
Jun 30 2022	n/a	n/a	JP¥197b
Mar 31 2022	JP¥2b	JP¥281m	JP¥230b
Dec 31 2021	n/a	n/a	JP¥439b
Sep 30 2021	n/a	n/a	JP¥473b
Jun 30 2021	n/a	n/a	JP¥431b
Mar 31 2021	JP¥2b	JP¥267m	JP¥376b
Dec 31 2020	n/a	n/a	JP¥181b
Sep 30 2020	n/a	n/a	JP¥56b
Jun 30 2020	n/a	n/a	JP¥120b
Mar 31 2020	JP¥2b	JP¥273m	JP¥44b

Tazminat ve Piyasa: Christophe P. 'ın toplam tazminatı ($USD 13.60M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 14.80M ).

Tazminat ve Kazançlar: Christophe P. 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Christophe P. Weber (59 yo)

11.9yrs

Görev süresi

JP¥2,161,000,000

Tazminat

Mr. Christophe P. Weber serves as Chief Executive Officer at Takeda Pharmaceutical Company Limited since April 2015 and as President and Representative Director since June 2014. He joined the firm on April...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christophe P. Weber	President	11.9yrs	JP¥2.16b	0.055% $ 28.2m
Milano Furuta	CFO & Director	2.1yrs	JP¥302.00m	0.0019% $ 999.0k
Andrew S. Plump	President of Research & Development and Representative Director	no data	JP¥1.20b	0.020% $ 10.2m
Seigo Izumo	Chair of Management Board	no data	Veri yok	Veri yok
Haruhiko Hirate	Member of Management Board	no data	Veri yok	Veri yok
Salvatore Alesci	Member of Management Board and Head of R&D Global Science & Biomedical Policy	no data	Veri yok	Veri yok
Michael Fox	Chief Operating Officer	no data	Veri yok	Veri yok
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	no data	Veri yok	Veri yok
Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	13.2yrs	Veri yok	Veri yok
Gabriele Ricci	Chief Data & Technology Officer	4.3yrs	Veri yok	0.0025% $ 1.3m
Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	5.7yrs	Veri yok	Veri yok
Natalie Furney	Global General Counsel	1.3yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

54.5yo

Ortalama Yaş

Deneyimli Yönetim: TKPH.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christophe P. Weber	President	11.9yrs	JP¥2.16b	0.055% $ 28.2m
Milano Furuta	CFO & Director	no data	JP¥302.00m	0.0019% $ 999.0k
Andrew S. Plump	President of Research & Development and Representative Director	10.9yrs	JP¥1.20b	0.020% $ 10.2m
John Michael Maraganore	Independent External Director	3.9yrs	JP¥43.00m	0.00024% $ 123.6k
Steven S. Gillis	Independent External Director	7.3yrs	JP¥49.00m	0.00050% $ 257.5k
Emiko Higashi	Independent External Director	9.9yrs	JP¥50.00m	0.00056% $ 288.4k
Yoshiaki Fujimori	Independent External Director	9.9yrs	JP¥40.00m	0.0012% $ 633.4k
Ian T. Clark	Independent External Director	7.3yrs	JP¥49.00m	0.00031% $ 159.6k
Jean-Luc Butel	Independent External Director	6.9yrs	JP¥51.00m	0.00024% $ 123.6k
Michel Orsinger	Independent External Director	9.9yrs	JP¥53.00m	0.00024% $ 123.6k
Masami Iijima	Independent External Chair	4.9yrs	JP¥43.00m	0.00041% $ 211.1k
Koji Hatsukawa	Independent External Director	9.9yrs	JP¥42.00m	0.00054% $ 278.1k

9.9yrs

Ortalama Görev Süresi

67.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TKPH.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.9 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/21 03:12
Gün Sonu Hisse Fiyatı	2026/05/21 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2026/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Takeda Pharmaceutical Company Limited 27 Bu analistlerden 14, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Takeda Pharmaceutical Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Announces Executive Changes, Effective June 2026

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Recent updates

Takeda Pharmaceutical Company Limited to Report Q2, 2027 Results on Oct 29, 2026

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 24, 2026

Takeda Pharmaceutical Company Limited Announces Positive Topline Results From Pivotal Phase 2/3 Clinical Trial Of TAK-881 In Primary Immunodeficiency Disease

Takeda Pharmaceutical Company Limited Announces Zasocitinib Delivers Rapid and Durable Skin Clearance in Plaque Psoriasis

Takeda Pharmaceutical Company Limited Announces Board and Executive Retirements

Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Company Announce National Third-Party Payor Class Certified in Lawsuit Regarding Actos

Takeda Pharmaceutical Company Limited to Report Q1, 2027 Results on Jul 30, 2026

Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera

Takeda Announces Positive Phase 3 Data Demonstrate Potential for ENTYVIO®? (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda Pharmaceutical Company Limited's Oveporexton (TAK-861) as A Potential First-In-Class Therapy for Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Revises Consolidated Earnings Guidance for the Fiscal Year 2025

Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-To-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment

Takeda Pharmaceutical Company Limited to Report Q3, 2026 Results on Jan 29, 2026

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

Wisner Baum Unleashes Rico Against Takeda Pharmaceuticals and Eli Lilly

Takeda Presents New Data Showing Mezagitamab Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy

Takeda Inc. Announces Completion of the 7-Year Pivotal Phase 3 Tides Trial Evaluating Its Dengue Vaccine, Qdenga®?V

Takeda Pharmaceutical Company Limited Declares Dividend for Second Quarter-End of Fiscal Year Ending March 31, 2026, Payable on December 1, 2025

Takeda Inc. Announces the Recently FDA- Approved Hyhub and Hyhub Duo Devices Now Available in the U.S. to Simplify Hyqvia® Infusion Preparation

Takeda Announces Executive Changes, Effective June 2026

Takeda Presents Orexin Data from Landmark Oveporexton Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda Announces U.S. FDA Approves Expanded Indication for VONVENDI for Adults and Children with Von Willebrand Disease

Takeda Pharmaceutical Company Limited to Report Q2, 2026 Results on Oct 30, 2025

Takeda Pharmaceutical Company Limited Announces an Embargoed Version of an Abstract for Phase 3 TAK-861-3002 Study (Radiantlight) of Oveporexton (TAK-861) in Narcolepsy Type 1, Which Is Slated to Be Presented At the Upcoming World Sleep 2025 Congress

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Fiscal Year 2025

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHub Duo Devices to Simplify HYQVIA Administration

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (Tak-861) in Narcolepsy Type 1

Takeda Pharmaceutical Company Limited Approves Dividend

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approval of Gammard Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda Pharmaceutical Company Limited Announces Change in Compensation Committee Members, Effective June 25, 2025

Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly

European Commission Approves Adcetris®? (Brentuximab Vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage Iib/Iii/Iv Hodgkin Lymphoma in Combination with Ecadd

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide

Takeda Announces The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 25, 2025

Takeda Pharmaceutical Company Limited Receives Approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli®? (Maralixibat) Oral Solution for the Treatment of Alagille Syndrome and Progressive Familial Intrahepatic Cholestasis in Japan

Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Announces Positive Topline Results from Phase 3 Verify Study of Rusfertide in Patients with Polycythemia Vera

Takeda Pharmaceutical Company Limited to Report Q1, 2026 Results on Jul 30, 2025

Takeda Pharmaceutical Company Limited (TSE:4502) announces an Equity Buyback for 28,500,000 shares, representing 1.8% for ¥100,000 million.

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)